Inactive Instrument

Other languages Coeptis Therapeutics, Inc. OTC Markets

Equities

COEP

US19207C1045

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26
Coeptis Therapeutics Holdings, Inc. Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK	Feb. 26
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-In-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections	Feb. 07
Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology	23-10-11
Coeptis Therapeutics Holdings, Inc. Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer	23-08-30
Coeptis Therapeutics Holdings, Inc. Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics	23-08-17
Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11
Coeptis Therapeutics Holdings, Inc Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic	23-08-01
Top Premarket Decliners	23-06-14
Coeptis Therapeutics Names Brian Cogley as Finance Chief	23-05-17
Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
Coeptis Therapeutics Gets Exclusive Right to Negotiate Deal With Deverra Therapeutics	23-04-18
Coeptis Therapeutics Obtains Exclusive Rights to Negotiate to Acquire VyGen-Bio	23-03-29
Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29
Coeptis Therapeutics Holdings, Inc. Auditor Raises 'Going Concern' Doubt	23-03-28
Top Premarket Gainers	23-03-27
Coeptis Therapeutics Partners With University of Pittsburgh to Advance Cell Therapy Development in Oncology	23-01-31
Coeptis Therapeutics Holdings, Inc. Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program	23-01-31
Coeptis Therapeutics Receives Non-Compliance Notice From Nasdaq	22-12-29

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Coeptis Therapeutics, Inc. OTC Markets

Equities

COEP

US19207C1045

Other languages

Filters